Ignaseclant Data for CMT Earns Spotlight Despite Mixed Trial Results

AARHUS, Denmark – February 12, 2026 – For the 135,000 Americans living with Charcot-Marie-Tooth disease (CMT), a progressive and debilitating nerve disorder with no approved treatments, any sign of therapeutic progress is significant. Today, Danish biotech firm NMD Pharma provided such a signal, announcing that data from its Phase 2a study of ignaseclant will be featured in a late-breaking oral presentation at the prestigious Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in March.

The selection elevates the visibility of a drug that produced a complex, yet promising, set of results, offering a potential new avenue for improving muscle function in a patient population long overlooked by pharmaceutical innovation. The presentation, to be delivered by Dr. W. David Arnold of the University of Missouri School of Medicine on March 11, will be scrutinized by thousands of clinicians and researchers, marking a pivotal moment for both NMD Pharma and the CMT community.

A Trial of Nuanced Success

NMD Pharma first shared top-line results from its SYNAPSE-CMT study on February 3, 2026, revealing a nuanced picture of ignaseclant's efficacy. The randomized, double-blind, placebo-controlled trial involved 81 adults with CMT types 1 or 2. The study did not meet its pre-specified primary endpoint: a statistically significant improvement in the 6-minute walk test (6MWT) compared to placebo after 21 days of treatment.

In drug development, missing a primary endpoint can often spell the end of a program. However, the story of ignaseclant is more complex. The company reported consistent and clinically meaningful improvements across a range of important secondary endpoints. Patients treated with the oral drug showed robust gains in handgrip strength and fine hand function—abilities crucial for daily tasks like buttoning a shirt, holding utensils, or using a keyboard, which are often severely compromised by CMT.

Furthermore, these objective functional gains were mirrored by patient-reported outcomes. Using the CMT-Health Index (CMT-HI), a specialized tool for measuring disease impact, patients on ignaseclant reported significant improvements in their physical function and overall quality of life. Adding to the intrigue, some of these functional gains were maintained even at a follow-up assessment 28 days after treatment had stopped, suggesting a durability of effect that extends beyond the drug's immediate presence in the body. The treatment was also well-tolerated, with no serious adverse events reported.

The Significance of a Late-Breaking Slot

The decision by the MDA to grant NMD Pharma a late-breaking oral presentation slot is a powerful endorsement. Such slots are fiercely competitive and reserved for research deemed to have a high and immediate impact on the field. The criteria typically require that the data was not available during the standard submission period, underscoring its novelty and importance.

For a drug that technically failed its primary goal, this selection suggests the conference's scientific committee saw profound value in the secondary findings. "The improvements in hand strength and dexterity are particularly relevant for patients," noted one neurologist familiar with CMT research, who spoke on the condition of anonymity. "While walking endurance is important, the loss of hand function is one of the most disabling aspects of the disease. Any therapy that can address this is a major step forward." This high-profile platform gives NMD Pharma an opportunity to present the full context of its data, arguing that the functional and patient-reported benefits represent a genuine therapeutic signal in a disease with no current treatments.

A Novel Mechanism in a Barren Landscape

Ignaseclant's approach is a departure from other strategies being explored for CMT. While many emerging therapies, such as gene therapies from companies like Sarepta Therapeutics, focus on correcting the underlying genetic defects specific to certain CMT subtypes, ignaseclant works differently. It is a first-in-class small molecule inhibitor of the skeletal muscle-specific chloride ion channel 1, or ClC-1.

In simple terms, ClC-1 acts as a brake on muscle activation. By inhibiting this channel, ignaseclant effectively "releases the brake," enhancing the muscle's excitability and allowing it to respond more forcefully to weak nerve signals. In CMT, where the peripheral nerves that control muscles progressively degenerate, this mechanism could help compensate for the failing nerve-to-muscle communication, thereby improving strength and function regardless of the specific genetic cause of the nerve damage.

This muscle-centric approach is what makes ignaseclant potentially applicable not only to various forms of CMT but also to other neuromuscular diseases. NMD Pharma is concurrently running Phase 2 trials for the drug in generalized myasthenia gravis (gMG) and spinal muscular atrophy (SMA), with results expected later in 2026. The U.S. Food and Drug Administration has already granted the drug Orphan Drug Designation for both CMT and gMG, a status that provides incentives for developing treatments for rare conditions.

The Path Forward for NMD Pharma

Despite the mixed top-line results, NMD Pharma has signaled its intent to accelerate the development of ignaseclant for CMT, buoyed by the secondary endpoint data and its recent financial strength. In November 2023, the company secured an approximately $80 million Series B financing round led by Jeito Capital, with strong participation from its existing syndicate of top-tier life science investors, including Novo Holdings and the Roche Venture Fund.

This capital is intended to fund the completion of its three ongoing Phase 2 studies and expand its pipeline. The company's strategy appears to be built on a deep belief in its ClC-1 inhibition platform. The upcoming MDA presentation will serve as a critical test of this strategy, as the company seeks to convince the scientific and investment communities that the functional benefits seen in the SYNAPSE-CMT study are the most important indicators of the drug's potential.

For the thousands of families affected by Charcot-Marie-Tooth disease, the journey of ignaseclant is a narrative of modern drug development—a path filled with complex data, scientific debate, and the persistent hope that innovation will eventually triumph over a devastating disease. The presentation in Orlando will not be an endpoint, but rather a crucial data point in a much longer story. The entire neuromuscular community will be watching closely.